This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implement...ing TB care and prevention and R&D into new tools. This Global Plan has already informed the Global Fund Investment Case and the 2022 G20 deliberations on TB. It will serve as a key document for inspiring and aligning global advocacy efforts, such as for the upcoming UNHLM on TB in 2023.
more
Southern African Journal of HIV Medicine
ISSN: (Online) 2078-6751, (Print) 1608-9693
http://www.sajhivmed.org.za
Published: 23 May 2018
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
New England Journal of Medicine 374:1,pp23-32
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.
more
Lancet 2013; 381: 1405–16
Series: Childhood Pneumonia and Diarrhoea no.1
2018
9th Edition
Offering information on HIV/AIDS treatment, prevention, and research
Lancet Glob Health 2020Published OnlineDecember 10, 2020 https://doi.org/10.1016/S2214-109X(20)30460-5
Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.
Orientations provisoires 19 juillet 2021
Nature | Vol 600 | 2 December 2021 |
BMJ Open Science 2021;5:e100202. doi:10.1136/
bmjos-2021-100202
Revised and expanded version of the Guidelines